ThromboGenics says that a mid-stage trial of microplasmin demonstrated positive results for a back-of-the-eye disease. And researchers said that the safety profile of the drug was so good that they decided to recruit an additional 15 patients to test a higher dosage of the drug. They will present their data at the annual meeting of the American Society of Retina Specialists.
- take a look at this release
- here's the AFX report on the data